Skip to content
2000
Volume 17, Issue 11
  • ISSN: 1573-4056
  • E-ISSN: 1875-6603

Abstract

Bone metastases are a common source of malignancy in the skeleton and occur much more often than primary bone cancer. Several works were being performed to identify early markers for bone metastasis and novel drug targets to improve patients' quality of life. As some concerns exist with the [18F]sodiumfluoridein positron emission tomography (PET) bone imaging, there has been an increase in the number of targeted radiopharmaceutical markers for bone metastases imaging in its competitor, 68Ga. Since 18F properties are superior to those of 68Ga, there is a distinct motivation for developing 18F radiopharmaceuticals for bone metastases imaging.

Loading

Article metrics loading...

/content/journals/cmir/10.2174/1573405617666210216091202
2021-11-01
2025-07-08
Loading full text...

Full text loading...

/content/journals/cmir/10.2174/1573405617666210216091202
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test